Rho Ventures Iv SC 13D/A Anacor Pharmaceuticals / RHO VENTURES IV ownership change

CUSIP No. 032420101 

Exhibit 3

JOINT FILING STATEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the beneficial ownership of Common Stock, $0.001 par value per share, of Anacor Pharmaceuticals Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Date: October 25, 2011

RHO VENTURES IV QP LP RHO VENTURES IV LP
By	its General Partner, Rho Management Ventures IV L.L.C.
By:	/s/ Jeffrey I. MartinJeffrey I. Martin
	Authorized Signer
RHO MANAGEMENT VENTURES IV L.L.C.
By:	/s/ Jeffrey I. MartinJeffrey I. Martin
	Authorized Signer
RHO VENTURES IV GMBH & CO BETEILIGUNGS KG
By	its General Partner, Rho Capital Partners Verwaltungs GmbH
By:	/s/ Jeffrey I. MartinJeffrey I. Martin
	Authorized Signer
RHO CAPITAL PARTNERS VERWALTUNGS GMBH
By:	/s/ Jeffrey I. MartinJeffrey I. Martin
	Authorized Signer
RHO VENTURES IV HOLDINGS, LLC
By:	/s/ Jeffrey I. MartinJeffrey I. Martin
	Authorized Signer
/s/ Jeffrey I. Martin
Jeffrey I. Martin, as Authorized Signer, on behalf of Mark Leschly

CUSIP No. 032420101 

/s/ Jeffrey I. Martin

Jeffrey I. Martin, as Authorized Signer, on behalf of Habib Kairouz

/s/ Jeffrey I. Martin

Jeffrey I. Martin, as Authorized Signer, on behalf of Joshua Ruch